Interleukin-10 (IL-10) and interleukin-6 (IL-6) have been reported to be related to hepatocellular carcinoma (HCC) prognosis. This study aimed to investigate the clinical usefulness of serum levels of IL-6 and IL-10 as biomarkers for HCC among high-risk patients.
Materials and Methods. 80 individuals were enrolled in this study; they were categorized into 4 groups: group 1 healthy individuals (NC) (n=20), group 2 chronic hepatitis C virus (HCV) patients (n=20), group 3 cirrhotic patients (LC) (n=20), and HCC group (n=20). Using ELISA technique serum levels of IL-6, IL-10, and alpha fetoprotein (AFP) were evaluated in all groups. Results. The mean serum levels of IL-6 were significantly higher in HCC than in LC, HCV, and NC groups (13.99±1.80, 7.49±0.43, 5.78±0.74, and 2.57±0.31), respectively (P<0.05); also the serum levels of IL-10 were significantly higher in HCC compared with LC, HCV, and NC groups (13.69±1.89, 7.37±0.53, 5.18±0.6, and 3.31±0.42) (P<0.05). We also found that the tumor size is correlated strongly with IL-6 and IL-10 levels (r=0.925, P<0.001; r=0.821, P<0.001), respectively.
Conclusion. The combination of those markers may help to identify a group of HCC patients with low AFP.
Serum Interleukin-10 But Not Interleukin-6 Is Related to Clinical Outcome in Patients With Resectable Hepatocellular Carcinoma
